UBE2T and Friedreich ataxia: Importantly, in vitro and cellular experiments indicated that these compounds do not act as traditional inhibitors of UBE2T; instead, they inhibit the FA pathway by disrupting the ubiquitination reaction mediated by UBE2T and FANCL.